These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 32105674)
1. Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases. Schiano C; Benincasa G; Franzese M; Della Mura N; Pane K; Salvatore M; Napoli C Pharmacol Ther; 2020 Jun; 210():107514. PubMed ID: 32105674 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic-related therapeutic challenges in cardiovascular disease. Schiano C; Vietri MT; Grimaldi V; Picascia A; De Pascale MR; Napoli C Trends Pharmacol Sci; 2015 Apr; 36(4):226-35. PubMed ID: 25758254 [TBL] [Abstract][Full Text] [Related]
3. Curcumin and cardiovascular diseases: Focus on cellular targets and cascades. Pourbagher-Shahri AM; Farkhondeh T; Ashrafizadeh M; Talebi M; Samargahndian S Biomed Pharmacother; 2021 Apr; 136():111214. PubMed ID: 33450488 [TBL] [Abstract][Full Text] [Related]
4. Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients. Napoli C; Benincasa G; Schiano C; Salvatore M Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):239-247. PubMed ID: 31665258 [TBL] [Abstract][Full Text] [Related]
5. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target. Zhou H; Li N; Yuan Y; Jin YG; Guo H; Deng W; Tang QZ Basic Res Cardiol; 2018 Aug; 113(5):37. PubMed ID: 30094473 [TBL] [Abstract][Full Text] [Related]
6. Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases. Altara R; Manca M; Brandão RD; Zeidan A; Booz GW; Zouein FA Clin Sci (Lond); 2016 Apr; 130(7):463-78. PubMed ID: 26888559 [TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders. Henning RJ; Bourgeois M; Harbison RD Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072 [TBL] [Abstract][Full Text] [Related]
9. Advances in epigenetic regulation of vascular aging. Jin J; Liu Y; Huang L; Tan H Rev Cardiovasc Med; 2019 Mar; 20(1):19-25. PubMed ID: 31184092 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic Regulation of Autophagy in Cardiovascular Pathobiology. Bu S; Singh KK Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207151 [TBL] [Abstract][Full Text] [Related]
11. Fluid-based assays and precision medicine of cardiovascular diseases: the 'hope' for Pandora's box? Benincasa G; Mansueto G; Napoli C J Clin Pathol; 2019 Dec; 72(12):785-799. PubMed ID: 31611285 [TBL] [Abstract][Full Text] [Related]
12. The role of redox signaling in epigenetics and cardiovascular disease. Kim GH; Ryan JJ; Archer SL Antioxid Redox Signal; 2013 May; 18(15):1920-36. PubMed ID: 23480168 [TBL] [Abstract][Full Text] [Related]
13. Involvement of Epigenetic Control and Non-coding RNAs in Cardiovascular System. Sharma S; Mishra A; Ashraf MZ Adv Exp Med Biol; 2020; 1229():121-132. PubMed ID: 32285408 [TBL] [Abstract][Full Text] [Related]
14. Emergent expansion of clinical epigenetics in patients with cardiovascular diseases. Napoli C; Coscioni E; de Nigris F; Donatelli F Curr Opin Cardiol; 2021 May; 36(3):295-300. PubMed ID: 33605616 [TBL] [Abstract][Full Text] [Related]
15. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation. Chistiakov DA; Orekhov AN; Bobryshev YV Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009 [TBL] [Abstract][Full Text] [Related]